07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-150 (miR-150); FMS-like tyrosine kinase 3 (FLT3; CD135); FMS-like tyrosine kinase 3 ligand (FLT3LG)

Cancer INDICATION: Acute myelogenous leukemia (AML); leukemia Patient sample, cell culture and mouse studies suggest miR-150, a negative regulator of FLT3, could help treat FLT3-driven AML and mixed lineage leukemia (MLL). miR-150 levels were lower in blood...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: FMS-like tyrosine kinase 3 ligand (FLT3LG); BRAF; programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)

Cancer INDICATION: Melanoma Mouse studies suggest FLT3LG plus poly I:C could help treat BRAF-mutant melanoma. In a mouse model of BRAF-mutant melanoma, systemic injection of FLT3LG plus intratumoral injection of poly I:C decreased tumor growth compared with...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

CDX-301: Interim Phase II data

Interim data from 3 sibling-matched donors for allogeneic hematopoietic stem cell transplant (HSCT) recipients with hematologic malignancies in an open-label, U.S. Phase II trial showed that 75 ug/kg/day subcutaneous CDX-301 given to the donor for...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

CDX-301: Pilot trial started

Celldex began an open-label, U.S. pilot trial to evaluate CDX-301 for 5 or 7 days alone and in combination with Mozobil plerixafor in up to 18 human leukocyte antigen (HLA)-matched donor/recipient sibling pairs....
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

CDX-301: Phase I data

Data from 18 healthy volunteers in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily subcutaneous CDX-301 for 5-10 days was well tolerated up to 25 µg/kg. There was 1 dose-limiting toxicity (DLT) of...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Clinical News

CDX-301: Phase I started

Celldex began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1-75 mg/kg IV or subcutaneous CDX-301 for 5-10 days in about 30 healthy volunteers. Celldex has exclusive rights to develop and commercialize CDX-301 from...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma FMS-like tyrosine kinase 3 ligand (FLT3LG) Mouse studies suggest FLT3LG could help increase the potency of...
07:00 , Aug 12, 2010 |  BC Innovations  |  Tools & Techniques

Macrophage express to the brain

Box 1. Macrophage express to the brain. Whereas Pedro Lowenstein of Cedars-Sinai Medical Center hopes to use gene therapy to deliver FMS-like tyrosine kinase 3 ligand (FLT3LG; FLT3L) to treat brain tumors, a University of South...
07:00 , Aug 12, 2010 |  BC Innovations  |  Tools & Techniques

Dendritic cell dragnet

The inability of peripheral immune cells to penetrate the CNS protects the brain against inflammation but has thwarted efforts to stimulate immunity against brain cancer antigens. Now a team at Cedars-Sinai Medical Center has devised...
07:00 , Aug 12, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Cancer vaccine adjuvant for the brain A study in mice suggests that FMS-related tyrosine kinase 3 ligand (FLT3LG; FLT3L)...